,

New Pain Killer on the Market: Suzetrigine

11 Kapseln mit gelb und schwarzen Partikeln auf einem Tisch.

Guest Article by Dr. Pradeep Chopra

Summary

  • The medicine is sold as Journavx, with the chemical name Suzetrigine.
  • It works by blocking NaV1.8 channels, which are responsible for pain transmission along nerves.
  • It only affects peripheral nerves (outside the brain and spinal cord), such as those in the arms and legs.
  • It does not cause addiction.
  • However, Journavx is weaker than Vicodin in controlling pain.
  • It is more effective for acute post-operative pain but not for chronic pain.
  • It failed in the treatment of low back pain.

What is Suzetrigine?

Suzetrigine, marketed under the brand name Journavx, is a novel non-opioid analgesic recently approved by the U.S. Food and Drug Administration (FDA)for the treatment of moderate-to-severe acute pain in adults. Developed by Vertex Pharmaceuticals, Suzetrigine represents the first new class of pain medication approved in over two decades.

Mechanism of Action

Suzetrigine functions as a selective inhibitor of the NaV1.8 sodium channel, which is predominantly expressed in peripheral pain-sensing neurons (nociceptors). By targeting this specific channel, Suzetrigine modulates pain transmission without affecting the central nervous system (CNS), thereby reducing the risk of addiction associated with opioid therapies.

Clinical Efficacy

The efficacy of Suzetrigine was demonstrated in two randomized, double-blind, placebo- and active-controlled trials involving patients undergoing abdominoplasty and bunionectomy surgeries. In both studies:

  • Patients receiving Suzetrigine reported a significant reduction in paincompared to those receiving a placebo.
  • However, Suzetrigine did not outperform opioids (hydrocodone and acetaminophen) in pain relief.
  • While not as strong as opioids, it provided effective pain relief without the risks of addiction.

Benefits

  • Non-Opioid Alternative: A new option for acute pain management without the risk of opioid addiction.
  • Targeted Mechanism: By selectively inhibiting the NaV1.8 sodium channel, Suzetrigine specifically modulates pain signals in peripheral neurons, potentially leading to fewer CNS side effects.

Risks and Adverse Effects

In clinical trials, the most commonly reported adverse reactions included:

  • Itching
  • Muscle spasms
  • Elevated blood levels of creatine phosphokinase
  • Rash

Suzetrigine is contraindicated with strong CYP3A inhibitors. Patients are also advised to avoid consuming grapefruit products during treatment due to potential drug interactions.

Considerations

While Suzetrigine has shown promise in acute pain management, its effectiveness in chronic pain conditions is questionable.

  • A Phase 2 study on lumbosacral radiculopathy did not show significant benefits over a placebo.
  • This highlights the limitations of Suzetrigine in chronic pain and the need for further research.

Conclusion

In summary, Suzetrigine is not a very impressive painkiller. It has weak pain-relieving properties, is only effective in acute surgical pain, and does not work for chronic pain. As with any medication, its benefits should be weighed against its potential risks, and individual patient needs must be considered when determining the best pain management strategy.

‍First published here: https://www.painri.com/post/new-painkiller-suzetrigine-journavx-ehlers-danlos-syndrome-crps

/by
You might also like
Mid-size shot of a woman with short, brown hair and a pink flower in her hair. She is wearing retro-style glasses and a neck brace and talks to a man which we can see from behind.Behind the Scenes: Meet the Filmmaker
Belo Cipriani, a young man with black, short hair wears a blue shirt and black jeans and sits on stone steps in front of a sea of pink flowers. One hand lies on the back of his guide dog, a black labrador.Firsts – The Mini Documentary Series for Belo Cipriani
Dr. Lilian Holm on EDS & Physical Therapy. Dr. Lilian Holm, a woman with shoulder-long brown hair and bangs, is sitting in her office, which is a large room with a turquoise wall behind her and an open fireplace. She sits on a beige chair and wears a black shirt and a delicate golden necklace. In the background is a treatment bench in the foreground two red flowers.EDSed Episode 2: Dr. Lilian Holm on Physical Therapy & EDS
Sarah, a woman with long blonde hair sits on her bed with a big box of medication in front of her.We Are Visible Too! Episode 1: Sarah Rightmire 
A woman with long brown hair bound to a ponytail sits in her garden on a chair with giraffe pattern. She smiles, wears a black shirt and sunglasses on top of her head.Interview with EDS advocate Donna Sullivan, TCAPP, about wrongful child abuse allegations and medically complex children
Karina, a woman with short, brown hair looks into the nothingness. She sits on stairs in the nature and is seen in profile. She wears four earrings. One of those is a dolphin, and the other one a turtle. Additionally, she wears a white-blue scarf around her neck brace.Karina Sturm ”Nothing about us without us!” – Producing ’We Are Visible’
The picture shows a person smiling at the camera, wearing a tie-dye shirt with yellow, pink, and blue colors. They have short hair, glasses, and a black neck brace with white trim. On their face, there is a small flower-shaped patch on their right cheek. They are holding up a feeding tube. Behind them is a background of various stuffed animals.Complicated – the must-watch documentary on Ehlers-Danlos Syndrome
a hand with purple gloves in a lab with a pipetteNorris Lab Finds HEDS Gene: Kallikrein
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *